Point-of-Care Testing Evaluated for Early Coagulopathy Diagnosis
|
By LabMedica International staff writers Posted on 09 Jun 2021 |

Image: The CoaguChek Pro II Coagulation Meter and CoaguChek PT Test Strips (Photo courtesy of Roche Diagnostics)
Hemorrhage and coagulopathy are particularly relevant complications and are often connected to injuries, surgical interventions, serious diseases, anticoagulant medication or pregnancy/delivery. Acute bleeding requires fast and targeted therapy and therefore, knowledge of the patient's potential to form a clot is crucial.
Treating bleeding complications, rapid hemostatic optimization (interventional, surgical, mechanical or medication) and targeted therapy are therapeutic goals and are therefore equivalent to those of coagulopathy treatment. The earlier a coagulopathy is diagnosed, the earlier a targeted therapy can be initiated. The international normalized ratio (INR) value is of particular importance for the diagnosis and therapy of coagulopathy.
Intensive Care Physicians at the University Hospital Frankfurt (Frankfurt, Germany) and their colleagues included in a study, one group that included hemorrhagic patients from the department of obstetrics (obstetric group = OG), and another group comprising patients admitted to the emergency department (emergency group = EG). The primary outcome measure was the difference between two INR results of one blood sample determined by point-of-care testing (POCT) and standard laboratory testing (SL).
After blood sampling, a drop of blood was applied immediately to the test stripe of the POCT device, CoaguChek Pro II (Roche Diagnostics GmbH, Mannheim, Germany). The CoaguChek Pro II is a portable device requiring an 8-μl sample volume. It measures the international normalized ratio (INR) based on an electrochemical reaction. Samples for SL analysis were sent to the central laboratory via a pneumatic dispatch system (EG) or personal-based transport (OG) for automated analysis with an ACL TOP 700 Hemostasis testing System, (Werfen GmbH, Munich, Germany) in combination with PT Re Combiplastin 2G reagents.
The team reported that INR results between POCT and SLA showed a high and significant correlation. POCT results were reported significantly more quickly (EG: 1.1 versus 39.6 minutes; OG: 2.0 versus 75 minutes) and required less time for analysis (EG: 0.3 versus 24.0 minutes; OG: 0.5 versus 45.0 minutes) compared to SLA. The time for transportation with the pneumatic tube was significantly shorter (8.0 versus 18.5 minutes) than with the personal-based transport system. The estimated blood loss was between 800 mL and 1300 mL.
The authors concluded that strip-based test systems may be suitable methods for the emergency diagnosis of hemorrhagic patients because their measurement results are available significantly more quickly and seem to support the use of point-of-care INR-devices to rule out pathological INR-values in bleeding patients. The test strip-based methods can be used as diagnostic elements in hemotherapy algorithms to implement fast and targeted hemotherapy that can positively impact the clinical outcomes of patients. The study was published on May 23, 2021 in the journal Practical Laboratory Medicine.
Related Links:
University Hospital Frankfurt
Roche Diagnostics
Werfen
Treating bleeding complications, rapid hemostatic optimization (interventional, surgical, mechanical or medication) and targeted therapy are therapeutic goals and are therefore equivalent to those of coagulopathy treatment. The earlier a coagulopathy is diagnosed, the earlier a targeted therapy can be initiated. The international normalized ratio (INR) value is of particular importance for the diagnosis and therapy of coagulopathy.
Intensive Care Physicians at the University Hospital Frankfurt (Frankfurt, Germany) and their colleagues included in a study, one group that included hemorrhagic patients from the department of obstetrics (obstetric group = OG), and another group comprising patients admitted to the emergency department (emergency group = EG). The primary outcome measure was the difference between two INR results of one blood sample determined by point-of-care testing (POCT) and standard laboratory testing (SL).
After blood sampling, a drop of blood was applied immediately to the test stripe of the POCT device, CoaguChek Pro II (Roche Diagnostics GmbH, Mannheim, Germany). The CoaguChek Pro II is a portable device requiring an 8-μl sample volume. It measures the international normalized ratio (INR) based on an electrochemical reaction. Samples for SL analysis were sent to the central laboratory via a pneumatic dispatch system (EG) or personal-based transport (OG) for automated analysis with an ACL TOP 700 Hemostasis testing System, (Werfen GmbH, Munich, Germany) in combination with PT Re Combiplastin 2G reagents.
The team reported that INR results between POCT and SLA showed a high and significant correlation. POCT results were reported significantly more quickly (EG: 1.1 versus 39.6 minutes; OG: 2.0 versus 75 minutes) and required less time for analysis (EG: 0.3 versus 24.0 minutes; OG: 0.5 versus 45.0 minutes) compared to SLA. The time for transportation with the pneumatic tube was significantly shorter (8.0 versus 18.5 minutes) than with the personal-based transport system. The estimated blood loss was between 800 mL and 1300 mL.
The authors concluded that strip-based test systems may be suitable methods for the emergency diagnosis of hemorrhagic patients because their measurement results are available significantly more quickly and seem to support the use of point-of-care INR-devices to rule out pathological INR-values in bleeding patients. The test strip-based methods can be used as diagnostic elements in hemotherapy algorithms to implement fast and targeted hemotherapy that can positively impact the clinical outcomes of patients. The study was published on May 23, 2021 in the journal Practical Laboratory Medicine.
Related Links:
University Hospital Frankfurt
Roche Diagnostics
Werfen
Latest Hematology News
- New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
- Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
- Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
- Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
- New Marker Helps Detect Aggressive Multiple Myeloma Earlier
- New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
- AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
- Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Channels
Clinical Chemistry
view channel
Simple Whole-Blood Screen Identifies Elevated Bile Acids Linked to Liver Disease
Liver disease can progress silently until treatment options become more limited. Routine blood panels measure markers such as cholesterol, bilirubin, and triglycerides but typically do not include bile... Read more
Routine Urine Protein Testing Identifies Undiagnosed Chronic Kidney Disease
Chronic kidney disease (CKD) is a major cause of mortality worldwide and often progresses silently until advanced stages. Despite the availability of simple urine and blood tests, many cases remain undetected,... Read more
Longitudinal Heart Stress Assessment Improves Prediction of Cardiovascular Outcomes
Accurately predicting cardiovascular disease (CVD) risk in older adults is challenging when assessments rely on single, point-in-time biomarker measurements. Dynamic indicators that reflect evolving cardiac... Read more
Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma
Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read moreMolecular Diagnostics
view channel
Genetic Risk Score Identifies Type 1 Diabetes in MODY Testing
Accurately distinguishing maturity-onset diabetes of the young from type 1 diabetes is difficult in routine care, especially when onset occurs in adolescence or early adulthood. Although maturity-onset... Read more
Self-Collected HPV Testing Reaches Patients Missed by Routine Screening
Timely cervical cancer screening prevents progression from persistent high‑risk human papillomavirus (HPV) infection, yet many adults marginalized from care do not complete routine exams.... Read more
Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read morePathology
view channel
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
Glioma surgery depends on distinguishing infiltrative tumor from functional brain tissue, but microscopic spread beyond visible margins makes this difficult. Conventional frozen sections provide rapid... Read moreTechnology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read moreIndustry
view channel
AI-Powered Pathology Collaboration Supports Companion Diagnostic Development
Imagene AI has joined the Proscia Ready partner alliance to integrate its hematoxylin and eosin (H&E) screening tools and immunohistochemistry (IHC) image-analysis capabilities with Proscia’s Concentriq... Read more







